These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4730841)

  • 1. The pharmacokinetics of unchanged pindolol in patients with impaired renal function.
    Ohnhaus EE
    Br J Pharmacol; 1973 Mar; 47(3):620P-621P. PubMed ID: 4730841
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetics of azlocillin in impaired renal function and haemodialysis (author's transl)].
    Schurig R; Kampf D; Becker H; Förster D
    Arzneimittelforschung; 1979; 29(12a):1944-8. PubMed ID: 543896
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.
    Ohnhaus EE; Nüesch E; Meier J; Kalberer F
    Eur J Clin Pharmacol; 1974; 7(1):25-9. PubMed ID: 4853607
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
    Lavene D; Weiss YA; Safar ME; Loria Y; Agorus N; Georges D; Milliez PL
    J Clin Pharmacol; 1977; 17(8-9):501-8. PubMed ID: 893736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings: Digoxin dosage in patients with impaired kidney function.
    Dettli L; Ohnhaus EE; Spring P
    Br J Pharmacol; 1972 Feb; 44(2):373P. PubMed ID: 4668631
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacokinetics of indomethacin and indomethacin metabolites administered continuously to patients with healthy or damaged kidneys].
    Stein G; Kunze M; Zaumseil J; Traeger A
    Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):470-3. PubMed ID: 924701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between renal function and elimination kinetics of pindolol in man.
    Oie S; Levy G
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):115-6. PubMed ID: 1233259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pindolol availability in hypertensive patients with normal and impaired renal function.
    Chau NP; Weiss YA; Safar ME; Lavene DE; Georges DR; Milliez PL
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):505-10. PubMed ID: 913016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pindolol: disposition and metabolism in rhesus monkeys after chronic treatment.
    Maurer G; Donatsch P; Galliker H; Kiechel JR; Meier J
    Xenobiotica; 1981 Jan; 11(1):33-41. PubMed ID: 7222728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma level of pindolol (Visken) under long-term treatment, computed from pharmacokinetics after a single dose].
    Gugler R; Bodem G; Dengler HJ
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1689-91. PubMed ID: 1030082
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefapirin in patients with normal and impaired renal functions.
    Bergan T; Orjavik O; Brodwall EK
    Arzneimittelforschung; 1981; 31(10):1773-6. PubMed ID: 7198453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Cefmenoxime in normal and impaired renal function.
    Höffler D; Koeppe P
    Arzneimittelforschung; 1983; 33(2):269-72. PubMed ID: 6303362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three hour creatinine clearance test in health and disease.
    Shah CP; Trivedi PM
    Indian J Physiol Pharmacol; 1974; 18(2):116-9. PubMed ID: 4416640
    [No Abstract]   [Full Text] [Related]  

  • 20. Single and multiple dose pharmacokinetics of pindolol.
    Gugler R; Bodem G
    Eur J Clin Pharmacol; 1978 Mar; 13(1):13-6. PubMed ID: 639828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.